Related Experiment Video
Updated: Jun 9, 2026
05:37
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
Intravitreal Nilotinib Reduces Fibroblast Growth Factor-2 Levels in a Rat Model of Dispase-Induced Intraocular
Hakan Yildirim1, Hakan Veli Savaş2, Mehmet Balbaba1
1Department of Ophthalmology, Fırat University Hospital, Elazığ, Turkey.
Journal of Vitreoretinal Diseases
|June 8, 2026
Summary
Nilotinib, a tyrosine kinase inhibitor, may help modulate fibrotic processes in ocular inflammation. This study found it significantly reduced fibroblast growth factor-2 in a rat model, suggesting potential for treating eye diseases.
Area of Science:
- Ophthalmology
- Pharmacology
- Immunology
Background:
- Intraocular inflammation can lead to fibrosis and vision loss.
- Tyrosine kinase inhibitors are being explored for various therapeutic applications.
Purpose of the Study:
- To investigate the effect of nilotinib on cytokine profiles in a rat model of intraocular inflammation.
- To assess nilotinib's potential in modulating fibrotic processes in the eye.
Main Methods:
- A dispase-induced intraocular inflammation model was used in Sprague-Dawley rats.
- Rats were divided into control, sham, and nilotinib treatment groups.
- Cytokine levels (TGF-β, PDGF, FGF-2, VEGF, IL-1β) were measured using ELISA.
Main Results:
- Dispase induction significantly increased all measured cytokines compared to controls.
- Nilotinib treatment showed a trend towards reducing TGF-β, PDGF, VEGF, and IL-1β.
- Fibroblast growth factor-2 (FGF-2) levels were significantly decreased by nilotinib.
Conclusions:
- Nilotinib demonstrated potential in modulating fibrotic processes by reducing FGF-2.
- Further research with anatomic endpoints is needed to clarify nilotinib's role in treating ocular fibrotic diseases.
